Acting Attorney General Todd Blanche just pulled the trigger on a long-stalled policy shift, knocking marijuana down from the federal government’s most draconian category to something a little less hysterical. After more than 50 years lumped in with heroin and LSD, cannabis is getting a bureaucratic reality check.
“Under the decisive leadership of [President Trump], this Department of Justice is delivering on his promise to improve American healthcare,” he declared, making it clear who’s steering the ship. And make no mistake: this has Donald Trump written all over it.
The president had been grumbling just days earlier that bureaucrats were “slow-walking me on rescheduling.” Blanche obliged, announcing he was “immediately rescheduling FDA-approved marijuana and state-licensed marijuana from Schedule I to Schedule III” while also “ordering a new, expedited hearing with set deadlines, to fully reschedule marijuana.”
In plain English? The feds are finally admitting maybe pot doesn’t belong in the same legal dungeon as the hardest drugs on Earth.
For researchers, this is a green light decades in the making. Until recently, scientists had to jump through flaming hoops just to study cannabis — and for years, only one government-approved grow operation at the University of Mississippi supplied the stuff. Complaints about lousy quality and limited strains piled up. Now, with more authorized growers and looser rules, serious medical research might actually catch up to reality.
For the booming cannabis business? This is where things get really interesting — and very lucrative.
A wonky piece of the tax code, Section 280E, has long punished cannabis companies by denying them standard business deductions, as if they were running cartel operations instead of state-licensed storefronts. That changes now. With a lower classification, those businesses could save billions — yes, billions — overnight.
But before anyone starts hotboxing their living room in celebration, pump the brakes. This isn’t full legalization, and it’s not a cultural free-for-all. Schedule III still means federal controls, prescriptions, and a cautious FDA that hasn’t signed off on raw marijuana as medicine. Wall Street might get high on this news, but Main Street won’t feel it right away.
The irony here is thick enough to roll. For years, activists staged smoke-ins outside the White House, pleading with presidents like Barack Obama — himself no stranger to marijuana in his younger days — to make this exact move. They got lectures. Trump’s team? They got action.
“I promised to be the president of common sense. That is exactly what we’re doing,” Trump said when he first ordered the shift. And in classic Trump fashion, he didn’t stop there, arguing “the facts compel the federal government to recognize that marijuana can be legitimate in terms of medical applications when carefully administered.”
He even leaned into one of the more politically potent arguments: alternatives to opioids. Cannabis, he said, “may include [its] use as a substitute for addictive and potentially lethal opioid painkillers … This can do it in a much lesser way and can make people feel much better that are living through tremendous pain.”
And in a line sure to resonate with families facing end-of-life care, Trump added marijuana could help patients “die with dignity” while keeping “their senses about them, as opposed to painkillers.”
Still, don’t confuse this with a full embrace of the pot lobby. The administration has walked a careful line: giving reformers enough to cheer about while stopping well short of opening the floodgates.
